Clin2
NCT05718817Possibly a fitEnrolling by invitation

Long-term study of XEN1101 for people with epilepsy

Focal EpilepsyTonic-Clonic Seizures

Treatments studied

Part of Brain & nervous system clinical trials.

This study gives XEN1101 in an open-label way (everyone knows they’re getting the drug) to people who finished earlier epilepsy studies. It aims to see how the treatment continues to work and whether it’s safe over the long term.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
880 people
Ages
12 years and older
Study type
Interventional

Who can take part

  • You must agree to join in writing after learning the study risks and details (or your parent/guardian can consent for adolescents).
  • You must have completed the prior double-blind epilepsy study period and not left early or had major issues or serious side effects that would block you from continuing.
  • You (or your caregiver, if needed) should be able to understand study instructions and follow the study schedule.
  • You must be able to accurately track seizures using seizure diary records.
  • You must not have had conditions or side effects that would make study participation unsafe for you or prevent following the plan.
  • You should not start another experimental epilepsy treatment study or use an experimental medical device during this study or for 28 days after finishing.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06132893Recruiting· Phase 2/Phase 3
Testing BHV-7000 for hard-to-control focal seizures in adults

This study tests a new medicine called BHV-7000 for adults whose focal seizures (starting in one part of the brain) are not controlled by current treatments. The goal is to see if it can reduce seizures safely.

Phoenix, Arizona
NCT07238868Recruiting· Phase 2
Long-term safety study of CB03-154 for epilepsy

This study is a long-term follow-up for people with epilepsy who already completed a previous trial of the drug CB03-154. It checks if the drug remains safe and effective over more time.

Melbourne, Victoria
NCT06612775Not yet recruiting· Phase 2
Testing CB03-154 for adults with focal epilepsy

This trial tests a new medication, CB03-154, to see if it is safe and can reduce seizures in adults with focal epilepsy. You may be able to join if you have had focal epilepsy for at least 2 years and are on a stable dose of 1 to 3 anti-seizure medications.

NCT06443463Enrolling by invitation· Phase 2
Long-term safety of BHV-7000 in epilepsy

This study checks the long-term safety of BHV-7000 for people who already completed an earlier trial with this drug. You keep taking the same medicine while doctors watch for any side effects over time.

Birmingham, Alabama
NCT05076617Enrolling by invitation· Phase 3
Testing a long-acting rescue seizure medicine for prolonged seizures

This Phase 3 study tests the safety and side effects of Staccato alprazolam for teens and adults (12+) who have certain types of long-lasting seizures. It may help people by offering a specific medicine option aimed at stopping prolonged seizure episodes under close medical study.

Phoenix, Arizona
NCT07051629Recruiting· Phase 1
Testing a new epilepsy medicine for safety in healthy people and patients

This study tests a new medicine called SIF001 for safety. It first gives the medicine to healthy volunteers, and then to people with epilepsy who have seizures even while on their current medicines. The goal is to find a safe dose.

Tucson, Arizona

Hear when a new Focal Epilepsy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.